⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671744 | 0.84 | TP53 (0.54) | — | |
| SCHEMBL14314061 | 0.75 | — | — | |
| SCHEMBL14865592 | 0.71 | — | — | |
| SCHEMBL28344025 | 0.71 | — | — | |
| SCHEMBL11471964 | 0.71 | — | — | |
| SCHEMBL3254849 | 0.69 | — | — | |
| SCHEMBL246902 | 0.69 | — | — | |
| SCHEMBL152655 | 0.67 | — | — | |
| SCHEMBL3813175 | 0.67 | — | — | |
| SCHEMBL2664411 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276146-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC | 2020-09-03 | — | — | US | disclosed |
| US-10610507-B2 | Methods for the treatment of sialorrhea | NeuRx Pharmaceuticals LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190015371-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC | 2019-01-17 | — | — | US | disclosed |
| US-20170281585-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC (US) | 2017-10-05 | — | — | US | disclosed |
| US-20160151321-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC | 2016-06-02 | — | — | US | disclosed |
| WO-2014078059-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140135392-A1 | METHODS FOR THE TREATMENT OF SIALORRHEA | NeuRx Pharmaceuticals LLC (US) | 2014-05-15 | — | — | US | disclosed |
| EP-1286591-B1 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | WATSON PHARMACEUTICALS INC (US) | 2010-10-06 | — | — | EP | disclosed |
| EP-1286591-A4 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | WATSON PHARMACEUTICALS INC (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1455776-A4 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | BRIDGE PHARMA INC (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1455776-A1 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | Bridge Pharma, Inc. (US) | 2004-09-15 | — | — | EP | disclosed |
| CN-1454054-A | Treatment of smooth muscle hyperactivity with -oxybutynin and -desethyloxybutynin | WATERSON PHARMA INC (US) | 2003-11-05 | — | — | CN | disclosed |
| WO-2003066042-A1 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | BRIDGE PHARMA, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-1286591-A1 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | Watson Pharmaceuticals, Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6432446-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF 4-ETHYLAMINO-2-BUTYNYL CYCLOHEXYL-PHENYLGLYCOLATE AND/ OR ONE OR MORE OPTICALLY ACTIVE ISOMERS, AND SALTS TO TREAT DISORDERS INVOLVING THE URETHROGENITAL TRACT | BRIDGE PHARMA, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020002201-A1 | Non-arrhythmogenic metabolite of oxybutynin | BRIDGE PHARMA, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001093683-A1 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | WATSON PHARMACEUTICALS, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| US-6123961-A | WITHOUT CARDIOVASCULAR DEPRESSING ACTIVITY SIDE EFFECT, BY ADMINISTERING R(-)-4-DIETHYLAMINO-2-BUTYNYL CYCLOHEXYLPHENYLGLYCOLATE OR SALT, FREE OF ITS CORRESPONDING S-ENANTIOMER | BRIDGE PHARMA, INC. (US) | 2000-09-26 | — | — | US | disclosed |